Table 4. Budgetary impact (US$) of the scenarios evaluated and incremental costs (ranibizumab alone; bevacizumab alone), 2008–2011, Brazil.

Year	Reference Scenario	Costs, ranibizumab alone	Incremental cost, ranibizumab	Costs, bevacizumab alone	Incremental cost bevacizumab
2008	1,443,676,107.00	3,076,414,450.00	1,632,738,343.00	127,850,362.00	(1,315,825,745.00)
2009	1,304,484,526.00	3,203,310,999.00	1,898,826,473.00	133,123,959.00	(1,171,360,567.00)
2010	1,436,566,306.00	3,364,862,918.00	1,928,296,612.00	139,837,772.00	(1,296,728,534.00)
2011	1,335,237,773.00	3,388,648,570.00	2,053,410,796.00	140,826,261.00	(1,194,411,511.00)
Total	5,519,964,714.00	13,033,236,939.00	1,878,318,056.00	541,638,354.00	(4,978,326,359.00)

1 real = US$2.00.